We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+0.32%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$5.94B
AUM Growth
-$751M
Cap. Flow
-$607M
Cap. Flow %
-10.22%
Top 10 Hldgs %
40.52%
Holding
146
New
24
Increased
39
Reduced
15
Closed
40

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$179M
2
ALIT icon
Alight
ALIT
+$88M
3
XYZ
Block Inc
XYZ
+$77.8M
4
TWLO icon
Twilio
TWLO
+$73.7M
5
WRBY icon
Warby Parker
WRBY
+$53.8M

Top Sells

Rank Stock Value
1
GOOG icon
Alphabet (Google) Class C
GOOG
+$269M
2
UBER icon
Uber
UBER
+$193M
3
META icon
Meta Platforms (Facebook)
META
+$161M
4
PSFE icon
Paysafe
PSFE
+$156M
5
AAPL icon
Apple
AAPL
+$99.6M

Sector Composition

Rank Sector Weight
1 Healthcare 32.32%
2 Consumer Discretionary 19.04%
3 Technology 18.49%
4 Industrials 18.23%
5 Financials 4.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
51
Spyre Therapeutics
SYRE
$9.25B
$17.2M 0.29%
86,309
+2,545
+3% +$445K
PNT
52
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$17.1M 0.29%
2,225,000
+179,400
+9% +$1.64M
BOLT icon
53
Bolt Biotherapeutics
BOLT
$7.78M
$16.8M 0.28%
66,275
+18,571
+39% +$5.25M
HRTX icon
54
Heron Therapeutics
HRTX
$92.9M
$15.9M 0.27%
1,490,440
– –
SLDB icon
55
Solid Biosciences
SLDB
$900M
$14.3M 0.24%
398,280
– –
DICE
56
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$13.4M 0.23%
+410,000
New +$14M
KDNY
57
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$13.4M 0.23%
1,047,468
+79,445
+8% +$1.05M
KZR
58
DELISTED
Kezar Life Sciences
KZR
$12.2M 0.21%
140,996
– –
RKLB icon
59
Rocket Lab Corp
RKLB
$51.8B
$12.1M 0.2%
+750,000
New +$9.02M
SIOX
60
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$11.9M 0.2%
5,489,000
– –
CMRX
61
DELISTED
Chimerix, Inc.
CMRX
$11.8M 0.2%
1,907,620
+1,082,379
+131% +$7.44M
TERN
62
DELISTED
Terns Pharmaceuticals
TERN
$11.7M 0.2%
1,125,736
+600
+0.1% +$6.22K
CZOO
63
DELISTED
Cazoo Group Ltd
CZOO
$11.7M 0.2%
755
-746
-50% -$14M
INZY
64
DELISTED
Inozyme Pharma
INZY
$11.4M 0.19%
986,400
+621,228
+170% +$9.69M
RXDX
65
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$11.4M 0.19%
480,480
-145,145
-23% -$3.43M
FSRX
66
DELISTED
FinServ Acquisition Corp. II Class A Common Stock
FSRX
$10.6M 0.18%
1,092,600
– –
BCAB icon
67
BioAtla
BCAB
$5.74M
$10.4M 0.18%
+7,084
New +$13.8M
IRON icon
68
Disc Medicine
IRON
$2.97B
$8.64M 0.15%
71,261
+94
+0.1% +$12.8K
IFRX icon
69
InflaRx
IFRX
$271M
$8.51M 0.14%
3,285,000
– –
EVLV icon
70
Evolv Technologies
EVLV
$1.1B
$8.21M 0.14%
+1,367,870
New +$10.8M
CHRS icon
71
Coherus Oncology
CHRS
$196M
$7.86M 0.13%
+489,333
New +$7.17M
MOLN
72
Molecular Partners
MOLN
$152M
$7.84M 0.13%
400,000
– –
NRDY icon
73
Nerdy
NRDY
$96.7M
$6.99M 0.12%
+700,000
New +$7.07M
ACHR icon
74
Archer Aviation
ACHR
$4.26B
$6.66M 0.11%
+750,000
New +$6.8M
ACIU icon
75
AC Immune
ACIU
$240M
$6.46M 0.11%
+963,500
New +$6.9M
1 2
3
4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Suvretta Capital Management held 146 positions worth $5.94B, down 11% from $6.69B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Suvretta Capital Management withdrew a net $607M in Q3 2021, closing 40 positions and reducing 15 holdings. Its most notable exit was Alphabet (Google) Class C, an estimated $269M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Suvretta Capital Management opened a new position in Thermo Fisher Scientific worth $186M.

  • Suvretta Capital Management's largest Q3 2021 buy was Thermo Fisher Scientific: 325,810 shares worth $186M.
  • Suvretta Capital Management added most to Twilio in Q3 2021, an estimated $73.7M increase.
  • Suvretta Capital Management's biggest Q3 2021 reduction was Medtronic, cutting an estimated $50.1M.
  • Suvretta Capital Management fully exited Alphabet (Google) Class C in Q3 2021, selling an estimated $269M.
  • Suvretta Capital Management's ten largest holdings make up 41% of its $5.94B portfolio in Q3 2021.
  • Suvretta Capital Management opened 24 new positions and closed 40 in Q3 2021.
  • Suvretta Capital Management's portfolio value fell 11% quarter-over-quarter to $5.94B.

Based on Suvretta Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.